Interactive discussion: what are the implications of SGLT2 inhibition for CV risk reduction in a multi-risk patient population?
Topic:
Diabetes management
Organised by Academic Medical Center Amsterdam. Dept Vascular Medicine and Physicians' Academy for Cardiovascular Education / Course Director: Prof John Kastelein / Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly
Event:
ESC Congress 2016
Congress Presentation
About the speakers
Professor John Eric Deanfield
University College London, London (United Kingdom of Great Britain & Northern Ireland)
50
presentations
3
followers
Professor Silvio Inzucchi
New Haven (United States of America)
5
presentations
0
follower
2 more presentations in this session
Introduction - SGLT2 inhibition in the management of CV risk & T2DM: ask the experts.
Speaker: Professor J. Deanfield (London, GB)
SGLT-2 inhibitors in the management of CVD and T2DM: brief update on results of the EMPA-REG OUTCOME trial.
Speaker: Professor S. Inzucchi (New Haven, US)
Access the full session
SGLT2 inhibition in the management of CV risk & T2DM: ask the experts
Speakers:
Professor J. Deanfield, Professor S. Inzucchi, Professor J. Deanfield, Professor S. Inzucchi
About the event
ESC 365 is supported by
